Rebecca Miksad, MD, MPH

Senior Scientist Rebecca Miksad
Assistant Professor of Medicine, Harvard Medical School
Attending Physician in Gastrointestinal Malignancies, Beth Israel Deaconess Medical Center
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Fax: 617-726-9414
Location: Institute for Technology Assessment
Massachusetts General Hospital
101 Merrimac St., 10th FL
Boston, MA 02114

Rebecca is engaged in oncology health services and outcomes research as a Senior Scientist with the Institute for Technology Assessment, an attending oncologist specializing in gastrointestinal malignancies at Beth Israel Deaconess Medical Center (BIDMC) and an Instructor in Medicine at Harvard Medical School. Her current and past research support includes the PCORT fellowship, the Young Investigator’s Award from the American Society of Clinical Oncology, the Timely Special Opportunity Award from the Dana-Farber Cancer Institute, the NIH Loan Repayment Program and the Clinical Research Feasibility Fund Award from BIDMC. Recent awards include the Lee Lusted Prize for outstanding research from the Society for Medical Decision Making and the Clinical Research Award from the Eastern Cooperative Oncology Group.

Rebecca received a B.A in economics from Harvard, an MD with honors in research from Cornell University, and an MPH from Harvard. She completed her internal medicine residency at New York-Presbyterian Hospital and her Hematology/Oncology fellowship at BIDMC. She completed the NCI-funded post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT). Rebecca’s research goals are to improve oncology treatment decision making through better characterization of cancer patient outcomes, improved accuracy of clinical endpoints, assessment of the economic implications of cancer therapy and application of decision analysis tools.

In the Spring of 2011, Rebecca recorded a podcast entitled "Pathologic Complete Response and Toxicity Results from the STAR-01 Trial Evaluating the Addition of Oxaliplatin to Neodjuvant Chemoradiation for Locally Advanced Rectal Cancer"


  • Martin, R. C., Bruenderman, E., Cohn, A., Piperdi, B., Miksad, R., Geschwind, J.-F., Goldenberg, A., Sanyal, A., Zigmont, E., Babajanyan, S., Foreman, P., Mantry, P., McGuire, B. & Gholam, P. (2017). Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.. American journal of surgery, 213(4), 688-695. [Online version]
  • Burstein, H. J., Krilov, L., Aragon-Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., Groot, J. F., Devine, S. M., DuBois, S. G., El-Deiry, W. S., Epstein, A. S., Heymach, J., Jones, J. A., Mayer, D. K., Miksad, R., Pennell, N. A., Sabel, M. S., Schilsky, R. L., Schuchter, L. M., Tung, N., Winkfield, K. M., Wirth, L. J. & Dizon, D. S. (2017). Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , JCO2016715292. [Online version]
  • Kasumova, G. G., Miksad, R. & Tseng, J. F. (2016). Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.. Journal of oncology practice, 12, 924-925. [Online version]
  • Pectasides, E., Miksad, R., Pyatibrat, S., Srivastava, A. & Bullock, A. (2016). Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases: A Case Report and Review of the Literature.. Dig Dis Sci, .
  • Griffith, O. L., Griffith, M., Krysiak, K., Magrini, V., Ramu, A., Skidmore, Z. L., Kunisaki, J., Austin, R., McGrath, S., Zhang, J., Demeter, R., Graves, T., Eldred, J. M., Walker, J., Larson, D. E., Maher, C. A., Lin, Y., Chapman, W., Mahadevan, A., Miksad, R., Nasser, I., Hanto, D. W. & Mardis, E. R. (2016). A genomic case study of mixed fibrolamellar hepatocellular carcinoma.. Ann Oncol, . [Online version]